Last reviewed · How we verify
Tranexamic Acid (Topical)
Tranexamic Acid (Topical) is a Antifibrinolytic agent Small molecule drug developed by Total Definer Research Group. It is currently FDA-approved for Topical hemostasis and bleeding control in dermatological and surgical procedures, Melasma and post-inflammatory hyperpigmentation (off-label topical use). Also known as: Hexakapron, TXA.
Tranexamic acid inhibits the breakdown of blood clots by blocking plasminogen activation, reducing fibrinolysis and promoting hemostasis.
Tranexamic acid (topical) is a small molecule inhibitor of plasminogen, used in various clinical trials for conditions such as postoperative wound haemorrhage and femoral neck fracture. It has been studied in different dosing regimens, including high and low doses, and has been administered through topical application and intraarticular injection.
At a glance
| Generic name | Tranexamic Acid (Topical) |
|---|---|
| Also known as | Hexakapron, TXA |
| Sponsor | Total Definer Research Group |
| Drug class | Antifibrinolytic agent |
| Target | Plasminogen / Plasmin |
| Modality | Small molecule |
| Therapeutic area | Dermatology / Hemostasis |
| Phase | FDA-approved |
Mechanism of action
Tranexamic acid is an antifibrinolytic agent that competitively inhibits the conversion of plasminogen to plasmin, thereby preventing the degradation of fibrin clots. When applied topically, it reduces bleeding by stabilizing formed clots at the site of application. This mechanism makes it useful for controlling bleeding in surgical and dermatological procedures.
Approved indications
- Topical hemostasis and bleeding control in dermatological and surgical procedures
- Melasma and post-inflammatory hyperpigmentation (off-label topical use)
Common side effects
- Local irritation or erythema
- Allergic contact dermatitis
Key clinical trials
- Comparative Evaluation of Topical Metformin and Topical Tranexamic Acid in Melasma (NA)
- A Trial of Intraoperative Fibrin Sealant on Postoperative Recovery After Total Knee Replacement (PHASE4)
- Evaluation of the Efficacy of Oral Tranexamic Acid and Glutathione-assisted Microneedling in Treatment of Melasma (PHASE2, PHASE3)
- "Topical Tranexamic Acid With Flap Fixation: A Novel Approach to Minimize Post-operative Drainage and Surgical Site Infection in Patients Undergoing Modified Radical Mastectomy" (NA)
- Topical Tranexamic Acid to Reduce Blood Loss During Cesarean Delivery (EARLY_PHASE1)
- Effect of Intravenous and Topical Tranexamic Acid on Drain Output in Breast Reduction Surgery (PHASE4)
- Protest Trial: TXA vs Saline (PHASE3)
- A Randomized Control Trial Assessing the Effect of Topical Tranexamic Acid on Risk of Hematoma in Breast Surgery (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Tranexamic Acid (Topical) CI brief — competitive landscape report
- Tranexamic Acid (Topical) updates RSS · CI watch RSS
- Total Definer Research Group portfolio CI
Frequently asked questions about Tranexamic Acid (Topical)
What is Tranexamic Acid (Topical)?
How does Tranexamic Acid (Topical) work?
What is Tranexamic Acid (Topical) used for?
Who makes Tranexamic Acid (Topical)?
Is Tranexamic Acid (Topical) also known as anything else?
What drug class is Tranexamic Acid (Topical) in?
What development phase is Tranexamic Acid (Topical) in?
What are the side effects of Tranexamic Acid (Topical)?
What does Tranexamic Acid (Topical) target?
Related
- Drug class: All Antifibrinolytic agent drugs
- Target: All drugs targeting Plasminogen / Plasmin
- Manufacturer: Total Definer Research Group — full pipeline
- Therapeutic area: All drugs in Dermatology / Hemostasis
- Indication: Drugs for Topical hemostasis and bleeding control in dermatological and surgical procedures
- Indication: Drugs for Melasma and post-inflammatory hyperpigmentation (off-label topical use)
- Also known as: Hexakapron, TXA
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing